FDA Fast-Track Program Ends as Biotech Approval Calendar Enters a High-Risk Stretch
The FDA’s Fast-Track decision adds uncertainty to biotech timelines as priority reviews and target dates crowd the calendar through year-end…
Mirum Pharmaceuticals Keeps Buy Rating After Positive Trial Data
H.C. Wainwright reiterated its Buy rating on $MIRM after positive trial data, keeping attention on Mirum’s rare-disease pipeline.
Celcuity’s REVTORPYK Launch Builds Momentum as Competition and Regulation Loom
Celcuity says REVTORPYK is off to a strong early start, but regulatory complexity, competition and infrastructure needs remain key execution…
Alvotech Enters Pivotal Quarter With Three FDA Biosimilar Decisions Ahead
Alvotech faces three anticipated FDA decisions in the fourth quarter, creating a pivotal test for its commercial outlook and risk profile.
Capricor Therapeutics Shares Rise Ahead of Nov. 22 FDA Decision
CAPR shares are drawing speculative interest ahead of the FDA’s Nov. 22 decision, creating a binary catalyst for traders.
Gossamer Bio Price Target Cut as Analysts Diverge on NDA Outlook
Wedbush lowered its Gossamer Bio price target over regulatory uncertainty, while H.C. Wainwright and Chardan remain bullish on the NDA path.
AstraZeneca’s Omniose Acquisition Signals Continued Appetite for Preclinical Biotech Deals
AstraZeneca’s acquisition of Omniose highlights its pipeline-building strategy and the pharmaceutical sector’s continued interest in preclin…
Zura Bio Plunges 76% After Tibulizumab Fails Phase 2 Hidradenitis Trial
Zura Bio shares plunged 76% after tibulizumab failed a Phase 2 hidradenitis trial, prompting the company to discontinue development for the …
Vir Biotechnology’s Positive Phase 3 Hepatitis Delta Data Put $VIR in Focus
Vir Biotechnology’s positive Phase 3 ECLIPSE 1 readout may strengthen its regulatory outlook, but approval and valuation upside remain uncer…
Eli Lilly’s Foundayo Sleep Apnea Results Set Up 2026 FDA Filing
Positive late-stage sleep apnea data could broaden Eli Lilly’s Foundayo franchise beyond weight management, with a U.S. filing planned by ye…
RBC Initiates Eupraxia Coverage With Outperform Rating as Analysts Cite EP-104GI Data
RBC begins coverage of Eupraxia with an Outperform rating as analysts point to positive Phase 2b EP-104GI data and renewed investor interest…
Genmab Shares Rise 4% After FDA Approves Partnered Cancer Drug
Genmab shares rose 4% after FDA approval of a Johnson & Johnson-partnered cancer drug, sharpening focus on its oncology strategy.











